Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Clearside Biomedical reports positive trial results and strategic leadership changes

Clearside Biomedical's Q3 2024 earnings call highlighted promising trial results, financial stability, and strategic leadership changes.
The company's strengths lie in its innovative suprachoroidal platform, strong partnerships, and positive trial outcomes for wet AMD treatment.
While facing challenges in trial design and funding, Clearside Biomedical has opportunities in geographic atrophy treatment and flexible dosing strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ciulla will chair the Company's Scientific Advisory Board (SAB), sharing his medical expertise as a practicing retinal specialist and providing counsel on Clearside's ODYSSEY Phase 2b clinical trial and other suprachoroidal development programs.

Clearside Biomedical Announces Leadership Team Update

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders -

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022:

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham & Company Mayank Mamtani - B.

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial -

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events -

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS ® ) Across Multiple Therapeutic Areas using Clearside's SCS Microinjector ® -

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform

CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

Clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - CFO Conference Call Participants Stacy Lee - Stifel Rohit Bhasin - Needham & Company Yi Chen - H.C. Wainwright William Wood - B.

Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 -

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

- Transaction Supports Progression of CLS-AX Clinical Program - - Transaction Supports Progression of CLS-AX Clinical Program -

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following investor conferences in August 2022:

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2022 financial results will be reported on Tuesday, August 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

- CLS-AX Dosing Completed in Cohorts 3 and 4 -

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

- Multiple Podium and Poster Presentations on XIPERE ® and Gene Therapy Delivery Utilizing SCS Microinjector ® -

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

- Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple Late-Stage Programs to Product Approval - - Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple Late-Stage Programs to Product Approval -

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham Julian Harrison - BTIG Operator Good day and thank you for standing by.

Clearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript

- First Approved Suprachoroidal Product, XIPERE ® , Now Commercially Available in U.S. -

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

- Multiple Poster Presentations on XIPERE ® and Gene Therapy Delivery Utilizing SCS Microinjector ® -

News for Clearside Biomedical Stock (CLSD)